Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients
Top Cited Papers
- 9 October 2019
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 11 (513)
- https://doi.org/10.1126/scitranslmed.aay2574
Abstract
There is a clear and unmet clinical need for biomarkers to predict responsiveness to chemotherapy for cancer. We developed an in vitro test based on patient-derived tumor organoids (PDOs) from metastatic lesions to identify nonresponders to standard-of-care chemotherapy in colorectal cancer (CRC). In a prospective clinical study, we show the feasibility of generating and testing PDOs for evaluation of sensitivity to chemotherapy. Our PDO test predicted response of the biopsied lesion in more than 80% of patients treated with irinotecan-based therapies without misclassifying patients who would have benefited from treatment. This correlation was specific to irinotecan-based chemotherapy, however, and the PDOs failed to predict outcome for treatment with 5-fluorouracil plus oxaliplatin. Our data suggest that PDOs could be used to prevent cancer patients from undergoing ineffective irinotecan-based chemotherapy.Keywords
Funding Information
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (2012-2022)
- KWF Kankerbestrijding (NKI2015-7732)
- KWF Kankerbestrijding (HUBR2014-7006)
This publication has 32 references indexed in Scilit:
- From tumour heterogeneity to advances in precision treatment of colorectal cancerNature Reviews Clinical Oncology, 2016
- Cancer treatment and survivorship statistics, 2016CA: A Cancer Journal for Clinicians, 2016
- Chemotherapy Use, Performance Status, and Quality of Life at the End of LifeJAMA Oncology, 2015
- Cancer drug resistance: an evolving paradigmNature Reviews Cancer, 2013
- TFAP2E–DKK4and Chemoresistance in Colorectal CancerThe New England Journal of Medicine, 2012
- Immunological aspects of cancer chemotherapyNature Reviews Immunology, 2008
- Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trialThe Lancet, 2007
- XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2004
- Survival of Patients With Advanced Colorectal Cancer Improves With the Availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the Course of TreatmentJournal of Clinical Oncology, 2004
- FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR StudyJournal of Clinical Oncology, 2004